You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
Measuring serum levels of the prostate-specific antigen (PSA) is the most common screening method for prostate cancer. However, PSA levels are affected by a number of factors apart from neoplasia. Notably, around 40% of the variability of PSA levels in the general population is accounted for by inherited factors, suggesting that it may be possible to improve both sensitivity and specificity by adjusting test results for genetic effects. To search for sequence variants that associate with PSA levels, we performed a genome-wide association study and follow-up analysis using PSA information from 15,757 Icelandic and 454 British men not diagnosed with prostate cancer. Overall, we detected a genome-wide significant association between PSA levels and single-nucleotide polymorphisms (SNPs) at six loci: 5p15.33 (rs2736098), 10q11 (rs10993994), 10q26 (rs10788160), 12q24 (rs11067228), 17q12 (rs4430796), and 19q13.33 [rs17632542 (KLK3: I179T)], each with Pcombined <3 × 10−10. Among 3834 men who underwent a biopsy of the prostate, the 10q26, 12q24, and 19q13.33 alleles that associate with high PSA levels are associated with higher probability of a negative biopsy (odds ratio between 1.15 and 1.27). Assessment of association between the six loci and prostate cancer risk in 5325 cases and 41,417 controls from Iceland, the Netherlands, Spain, Romania, and the United States showed that the SNPs at 10q26 and 12q24 were exclusively associated with PSA levels, whereas the other four loci also were associated with prostate cancer risk. We propose that a personalized PSA cutoff value, based on genotype, should be used when deciding to perform a prostate biopsy.
Footnotes
-
↵* These authors contributed equally to this work.
-
Citation: J. Gudmundsson, S. Besenbacher, P. Sulem, D. F. Gudbjartsson, I. Olafsson, S. Arinbjarnarson, B. A. Agnarsson, K. R. Benediktsdottir, H. J. Isaksson, J. P. Kostic, S. A. Gudjonsson, S.N. Stacey, A.Gylfason, A. Sigurdsson, H. Holm, U. S. Bjornsdottir, G. I. Eyjolfsson, S. Navarrete, F. Fuertes, M. D. Garcia-Prats, E. Polo, I. A. Checherita, M. Jinga, P. Badea, K. K. Aben, J. A. Schalken, I. M. van Oort, F. C. Sweep, B. T. Helfand, M. Davis, J. L. Donovan, F. C. Hamdy, K. Kristjansson, J. R. Gulcher, G. Masson, A. Kong, W. J. Catalona, J. I. Mayordomo, G. Geirsson, G. V. Einarsson, R. B. Barkardottir, E. Jonsson, V. Jinga, D. Mates, L. A. Kiemeney, D. E. Neal, U. Thorsteinsdottir, T. Rafnar, K. Stefansson, Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Sci. Transl. Med. 2, 62ra92 (2010).
- Copyright © 2010, American Association for the Advancement of Science
